Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated radiotherapy plus sintilimab, bevacizumab and pemetrexed after EGFR-TKI progression in non-squamous NSCLC
ChiCTR2400086018Phase 2Recruiting
- Sponsor
- Department of Oncology, Affiliated Hospital of Southwest Medical University
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab, bevacizumab, pemetrexed and cisplatin in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Department of Oncology, Affiliated Hospital of Southwest Medical University. Primary endpoint: Objective response rate (ORR). Started Jun 2024; status: recruiting.
02
Drugs
sintilimabbevacizumabpemetrexedcisplatin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2400086018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086018.